CriticalClass Ia antiarrhythmic with antimuscarinic activity×First-generation antihistamine with anxiolytic activity
Updated · Methodology
Mechanism
Hydroxyzine is associated with QT prolongation. After marketing, QT prolongation and torsade de pointes were reported, mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Disopyramide is a class IA antiarrhythmic and, like other drugs of this class, can prolong the QT interval and cause torsade de pointes (disopyramide label, US Food and Drug Administration, FDA). The Spanish hydroxyzine SmPC states that combining it with QT-prolonging drugs, disopyramide included, raises the risk of arrhythmia (AEMPS). A second mechanism is anticholinergic. Both drugs have atropine-like effects, and both Spanish SmPCs warn that these add up with other anticholinergic drugs (hydroxyzine and disopyramide SmPCs, AEMPS). Hydroxyzine is unlikely to change the metabolism of disopyramide, which goes through CYP3A4, because it inhibits this enzyme only at concentrations above peak plasma levels (hydroxyzine and disopyramide SmPCs, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Ventricular tachycardia, ventricular fibrillation and torsade de pointes, which disopyramide can cause, lead to palpitations, dizziness and fainting (disopyramide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The atropine-like effects of disopyramide include dry mouth, difficulty passing urine up to acute urinary retention with an enlarged prostate, constipation and blurred vision, and a rise in eye pressure in angle-closure glaucoma (disopyramide SmPC, AEMPS, and label, US Food and Drug Administration, FDA). In older people and with anticholinergic drugs, paralytic ileus may occur, and older people may also develop cognitive disturbances (disopyramide SmPC, AEMPS). Hydroxyzine itself causes drowsiness and dry mouth. Because of its anticholinergic effect, prescribe it with caution in glaucoma, bladder outflow obstruction, reduced gut motility, myasthenia gravis and dementia (hydroxyzine SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval or cause torsade de pointes and names disopyramide (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US hydroxyzine label only advises caution with class IA antiarrhythmics (hydroxyzine label, US Food and Drug Administration, FDA); the Spanish SmPC is stricter. Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Disopyramide is contraindicated in pre-existing long QT (disopyramide SmPC, AEMPS). During disopyramide treatment, monitor the QT interval and QRS duration and stop disopyramide if they lengthen by more than 25%. Monitor potassium and correct abnormal levels (disopyramide SmPC, AEMPS). If hydroxyzine and disopyramide have nevertheless been taken together and signs of arrhythmia appear, stop hydroxyzine (hydroxyzine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Disopiramida (nº registro 52549), sección 4.5 (2025)– AEMPS, CIMA, nº registro 52549 (Dicorynan), revisión 03/2025, secciones 4.3, 4.4 y 4.5
- FDA: Norpace (disopyramide) prescribing information (2026)– DailyMed setid e2aa1642-d262-4520-bc6a-9fd3ad795677, revisión 08/2026, Contraindications, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage